Referred Molecular Testing As a Barrier to Optimal Treatment Decision Making in Metastatic Non‐small Cell Lung Cancer: Experience at a Tertiary Academic Institution in Canada
CANCER MEDICINE(2024)
Key words
biomarkers,in-house testing,molecular testing,non-small cell lung cancer,targeted therapy,turnaround time
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined